Lead PI: Dr Shelagh B Coutts
Status: Recruiting
No. of Patients Currently Recruited: 139 No. of Patients Required: 1274
TEMPO-2 is examining the role of thrombolysis with low-dose (0.25mg/kg) tenecteplase for patients with minor stroke (NIHSS 0-5) and proven intracranial occlusion (defined by CTA or CTP) in reducing disability at 90 days after stroke onset. The study will enrol up to 1274 patients in Canada, Europe and Australia.
Trial URL:
https://clinicaltrials.gov/ct2/show/NCT02398656?term=TEMPO&cond=stroke&rank=1
NCT02398656
